Bispecific Antibodies Market, By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Application (BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others), By End-User (Hospitals, Clinics and Research Centers) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI467621 | Publish Date: May 2023 | No. of Pages: 192

Global Bispecific Antibodies Market Overview

Bispecific antibodies are artificial proteins where two or more antigen recognizing elements are combined together to form a single construct. Bispecific antibodies have the ability to bind with two or more targets at a time. The structure of the antibodies include quadromas, chemical heteroconjugates, bispecific antibodies with special heterodimerization domains and biospecific antibodies of minimal size. The advantages include dual targeting of disease mediators and delivering payloads to targeted site. FDA approved two bispecific antibody products Catumaxomab and blinatumomab. Many key players are conducting research on symmetric bispecific antibody. BEAT, duobody and crossmab are some of the asymmetric bispecific antibodies which are targeted by some major key players such as Eli Lilly and Company, Genmab A/S. The Bispecific Antibodies Market accounted for US$ 484.9 million in 2019 and is estimated to be US$ 915.4 million by 2029 and is anticipated to register a CAGR of 6.6%.

Global Bispecific Antibodies Market Dynamics

Increasing cancer patient and advancement in technologies for the treatment

The increase in mortality and morbidity rates among patients is one of the driver of this market. For instance, according to the WHO, there are approximately 14 million cancer cases every year and the rates are constantly increasing. Almost 1.9 million new cancer cases are expected to be diagnosed in 2021.

Increasing investments to harness the potential of highly effective bispecific antibody drug therapy

Various pharmaceutical companies are involved in the development and manufacture of bispecific antibodies. For instance, MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government funding is projected to further encourage research and development in the field of bispecific antibodies.

However, technical and clinical-related challenges might hamper the growth of the global market to a certain extent.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Bispecific Antibodies Market Segmentation

                                                                   

The Global Bispecific Antibodies Market is segmented based on type, application, end-user and region.

On the basis of type, the Global Bispecific Antibodies Market is segmented into Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597. On the basis of application, the target market is segmented into BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others. On the basis of end-user, the target market is segmented into hospitals, clinics and research centers.

Regional Insights:

                                                                         

On region the Global Bispecific Antibodies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are the dominating regions having largest market share of bispecific antibodies due to well-developed healthcare infrastructure, high cancer prevalence and presence of major key players in the regions. In addition, favorable initiatives taken by federal government also contribute for market growth of North American and European regions. Similarly, Asia Pacific is untapped market due to improper healthcare facilities in some Asian countries.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Type- Catumaxomab (Removab), Blinatumomab, Duligotumab and SAR 156597

By Application– BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others

By Site of Collection– Hospitals, Clinics and Research Centers

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Bispecific Antibodies Market report based on product, site of collection, application, and region.

 

                                                                                     

Global Bispecific Antibodies Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
      • Rest of Middle East & Africa

Global Bispecific Antibodies Market Key Players

The key players operating in the Global Bispecific Antibodies Market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc, Portola Pharmaceuticals, Inc., Sanofi S.A. and Others.

Global Bispecific Antibodies Market Company Profile

  • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Limited
  • GlaxoSmithKline plc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Pfizer, Inc
  • Portola Pharmaceuticals, Inc.
  • Others

 “*” marked represents similar segmentation in other categories in the respective section

Global Bispecific Antibodies Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Bispecific Antibodies Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By End-User
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Bispecific Antibodies Market, By Type 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Catumaxomab (Removab)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Blinatumomab
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Duligotumab
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • SAR 156597
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Bispecific Antibodies Market, By Application, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • BsMAb for Cancer Diagnostic
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • BsMAb for Diagnosis of Bacterial & Infectious Diseases
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • BsAbs Blocking Signaling Pathways
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    •  BsAbs Targeting Tumor Angiogenesis
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global Bispecific Antibodies Market, By End-User, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Clinics
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Research Centers
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global Bispecific Antibodies Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Limited
  • GlaxoSmithKline plc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Pfizer, Inc
  • Portola Pharmaceuticals, Inc.
  • Others
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Global Bispecific Antibodies Market is segmented based on type, application, end-user and region.

Rising initiatives by government bodies and advanced technologies are the major factor driving growth of the global market

North America and Europe are the dominating regions having largest market share of biospecific antibodies due to well-developed infrastructure healthcare and has highest number of various cancer patients with major key players in these regions.

The key players operating in the Global Bispecific Antibodies Market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc, Portola Pharmaceuticals, Inc., Sanofi S.A. and Others.